A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression.
Brandon M WeissDavid ErritzøeBruna GiribaldiDavid J NuttRobin Lester Carhart-HarrisPublished in: Journal of psychopharmacology (Oxford, England) (2023)
for measuring depression, as well as the practice of relying on individual scales that tend not to capture the multidimensional structure or core of depression. Using an alternative approach that captures depression more granularly and comprehensively yielded specific insight into areas where PT therapy may be particularly useful to patients and clinicians.
Keyphrases
- depressive symptoms
- sleep quality
- end stage renal disease
- healthcare
- chronic kidney disease
- primary care
- newly diagnosed
- clinical trial
- ejection fraction
- palliative care
- randomized controlled trial
- peritoneal dialysis
- study protocol
- mesenchymal stem cells
- combination therapy
- physical activity
- stem cells
- major depressive disorder
- smoking cessation
- data analysis
- big data
- artificial intelligence
- patient reported